Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy

AIDS

Volumn 13, Issue 2, 1999, Pages 185-194

  Martinon, Frédéric ^a   Michelet, Christian ^b   Peguillet, Isabelle ^c   Taoufik, Yassine ^c   Lefebvre, Philippe ^a   Goujard, Cécile ^c   Guillet, Jean Gérard ^a   Delfraissy, Jean François ^c   Lantz, Olivier ^c  

^a Institut Cochin   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Chemokine receptor; Cytokine; Highly active antiretrovival therapy; HIV; Quantitative PCR; T cell receptor repertoire

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; LAMIVUDINE; LYMPHOKINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE EXPRESSION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-4; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, MESSENGER; SAQUINAVIR; ZIDOVUDINE;

EID: 0032970758     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00006     Document Type: Article

References (39)

1. Cameron W, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
4. Rhone SA, Hogg RS, Yip B, et al.: The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
5. Autran B, Garcelain G, Li S, et al.: Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV-disease. Science 1997, 277:112-116.
6. Pakker NG, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T-cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-214.
7. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune responses of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
8. Li TS, Tubiana R, Katlama C, et al.: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-disease. Lancet 1998, 351:1682-1686.
9. Clerici M, Hakim FT, Venzon DJ, et al.: Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993, 91:759-765.
10. Clerici M, Shearer GM: A TH1 ◆ TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993, 14:107-111.
11. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D: Selective depletion in HIV infection of T-cells that bear specific T-cell receptor V sequences. Science 1991, 254:860-862.
12. Gea-Banacloche JC, Weiskopf EE, Hallahan C, et al.: Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T-cell receptor repertoire. J Infect Dis 1998, 177:579-585.
13. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.
14. Gorochov C, Neumann AU, Kereveur A, et al.: Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998, 4:215-221.
15. Tough DF, Borrow P, Sprent J: Induction of bystander T-cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
16. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL: TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994, 8:757-762.
17. Meyaard L, Hovenkamp E, Keet I, et al.: Single-cell analysis of IL-4 and IFN-γ: production by T-cells from HIV-infected individuals. J Immunol 1996, 157:2712-2718.
18. Fakoya A, Matear P, Filley E, et al.: HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS 1997, 11:1445-1452.
19. Rogge L, Barberis-Maino L, Biffi M, et al.: Selective expression of an interleukin-12 receptor component by human T-helper 1 cells. J Exp Med 1997, 185:825-831.
20. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997, 277:2005-2007.
21. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T-lymphocytes. Proc Natl Acad Sci USA 1997, 94:1925-1930.
22. Michelet C, Bellissant E, Delfraissy JF, et al.: Tolérance de l'Association ritonavir + saquinavir ajoutes à la poursuite d'une bithérapic par AZT + 3TC. Phase pilote (ANRS 069). XVII Interdisciplinary meeting on anti-infectious chemotherapy. Paris 1997.
23. Barry M, Gibbons S, Bark D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinical important pharmacokinetic considerations. Clin Phamacokinet 1997, 32:194-209.
24. Chomczynsky P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
25. Prévost-Blondel A, Lengagne R, Letourneur F, Pannetier C, Gomard E, Guillet JG: In vivo longitudinal analysis of a dominant TCR repertoire selected in human response to influenza virus. Virology 1997, 233:93-104.
26. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P: Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994, 153:2807-2818.
27. Wei S, Charmley P, Robinson MA, Concannon P: The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics 1994, 40:27-36.
28. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P: The sizes of the CDR3 hypervariable regions of the murine T-cell receptor: chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993, 90:4319-4323.
29. Alard P, Lantz O, Sebagh M, et al.: A versatile ELISA-PCR assay for mRNA quantitation from a few cells. Biotechniques 1993, 15:730-737.
30. Taoufik Y, Froger D, Benoliel S, Dussaix E, Delfraissy JF, Lantz O: Quantitative ELISA-PCR at saturation using homologous internal DNA standards and chemiluminescence revelation. Eur Cytokine Netw 1998, 9:197-204.
31. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A: An invariant Vα24-JαQ/Vβ11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 1994, 180:1171-1176.
32. Posnett DN, Sinha R, Kabak S, Russo C: Clonal populations of T-cells in normal elderly humans: the T-cell equivalent to 'Benign monoclonal gammapathy'. J Exp Med 1994, 179:609-618.
33. Estaquier RJ, Idziorek T, Zou W, et al.: T helper 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1) mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995, 182:1759-1767.
34. Levine BL, Mosca JD, Riley JL, et al.: Antiviral effect and ex vivo CD4+ T-cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996, 272:1939-1943.
35. Dauphinee MJ, Kipper SB, Wofsy D, Talal N: Interleukin-2 deficiency is a common feature of autoimmune mice. J Immunol 1981, 127:2483-2487.
36. 2 disease: paradoxical in vivo versus in vitro findings. Clin Exp Immunol 1988, 73:401-405.
37. Zurawski C, de Vries JE: Interleukin-13, an interleukin-4-like cytokine that acts on monocytes and B-cells, but not on T-cells. Immunol Today 1994, 15:19-26.
38. Zou W, Dulioust A, Fior R, et al.: Increased T-helper type 2 cytokine production in chronic HIV infection is due to interleukin (IL)-13 rather than IL-4 [letter]. AIDS 1997, 11:533-534.
39. Taoufik Y, Lantz O, Vallon C, Charles A, Dussaix E, Delfraissy JF: HIV gp120 inhibits IL-12 production by human monocytes: an indirect IL 10 mediated effect. Blood 1997, 89:2842-2848.